La sensibilización a Aspergillus fumigatus se asocia con bronquiectasias de alto riesgo

Fungal sensitization is an increasingly recognized endophenotype in chronic respiratory disease, however, its role in bronchiectasis remains poorly defined. This study aims to provide the most comprehensive evaluation to date of fungal sensitization and its clinical relevance in bronchiectasis using an expanded panel of crude and recombinant fungal allergens.

What is the prevalence and clinical implications of fungal sensitization in bronchiectasis?

We conducted an international, multi-centre evaluation of fungal sensitization across six tertiary centres in four countries (Singapore, Malaysia, United Kingdom and Italy) prospectively recruiting N=277 individuals with bronchiectasis. Using a comprehensive, expanded allergen panel including 11 crude and 24 recombinant fungal allergens (total: 35 allergens and 9,695 individual assays), we assessed sensitization responses in relation to clinical characteristics, exacerbation frequency and geographic origin. Low baseline exacerbations is defined as < 3, and high as ≥ 3 in the preceding 12 months of study recruitment.

Sensitization to recombinant Aspergillus fumigatus (rAsp f) links to bronchiectasis severity. Measurable responses to rAsp f allergens 12, 15, and 17 associates with severe (hospitalized) exacerbations. particularly in those with low baseline exacerbations (low-risk) . 'Sensitized' low-risk individuals demonstrate significantly greater disease severity and higher occurrence of bronchiectasis-COPD overlap (BCO) compared to non-sensitized, low-risk individuals , a relationship absent in those with high baseline exacerbations . Polysensitization to the same allergens confers further additional risks of severe (hospitalized) exacerbations. Notably, sensitized Asians to rAsp f allergens 12, 15, and 17 demonstrate poorest clinical outcomes with increased symptoms, poorer lung function, and severe disease.

Aspergillus fumigatus sensitization, particularly to rAsp f allergens 12, 15, and 17 is a clinically significant and potentially treatable trait in bronchiectasis. This is of highest relevance in individuals with lower baseline exacerbation frequency and Asian descent.